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Abstract: Lyme disease is the most common zoonotic bacterial disease in North America.
It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20%
of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized
fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is
no evidence for the presence of viable infectious organisms in individuals with posttreatment
Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population
in rodents and primates even after antibiotic treatment. Although such observations need more
ratification, there is unmet need for developing the therapeutic agents that focus on removing the
persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose,
high-throughput screening was done using BacTiter-Glo assay for four compound libraries to
identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries
containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were
screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National
Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We
subsequently identified 150 unique compounds, which inhibited .90% of B. burgdorferi growth
at a concentration of ,25 µM. These 150 unique compounds comprise many safe antibiotics,
chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules
based on safety and potency and studied their minimum inhibitory concentration and minimum
bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen
as lead molecules for further advanced studies.
Keywords: Lyme disease, Borrelia burgdorferi, BacTiter-Glo assay, high-throughput screening,
persisters
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Lyme borreliosis, commonly referred to as Lyme disease, is the most common zoonotic
bacterial disease in North America. It is estimated .300,000 cases per annum in USA
are reported.1 Lyme disease is caused by the spirochetes of genus Borrelia, collectively
known as Borrelia burgdorferi sensu lato. Among the genus, B. burgdorferi sensu
stricto (B. burgdorferi s.s.) is the single major causative agent of the disease in USA.
Other members in the group include Borrelia duttonii, Borrelia garinii, Borrelia afzelii,
and Borrelia miyamotoi, which are involved in infections in Europe, Eurasia, and other
parts of the world.2,3 Important clinical presentations of Lyme disease in humans include
erythema migrans, fatigue, fever, chills, muscle, and joint pain.4,5 Approximately
10%–20% of the patients who have been treated with antibiotic therapy reported the
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reappearance of symptoms, such as muscle and joint pain and
generalized fatigue. In some patients, these symptoms last
for .6 months after the initial treatment. Several researchers categorize this condition as posttreatment Lyme disease
syndrome (PTLDS), and it is observed in patients even after
rigorous antibiotic treatment.6 However, the reason for the
reoccurrence of these symptoms in some patients is unclear.
This might be due to the hyperresponsive immune reaction
to the deposited antigenic debris of the Borrelia or any drugtolerant persisters.7,8 Some researchers have raised the question that Borrelia may persist in some hosts after antibiotic
treatment, but the idea is controversial.9,10
In the absence of antibiotic therapy, B. burgdorferi can
affect immunocompetent host and can establish long-term
infections lasting years to lifelong in its natural (ie, mice) and
incidental (ie, humans) hosts.11,12 Although current animal
models (mice, dogs, and rhesus macaque monkeys) do not
completely mimic human infection, studies have shown that
antibiotic therapy with doxycycline, ceftriaxone, or tigecycline did not fully eradicate B. burgdorferi, as determined by
xenodiagnosis method.13–16 Many researchers have expressed
their concerns on how the previously mentioned studies were
conducted. Recent studies in mice showed a resurgence of
B. burgdorferi after 12 months of treatment with antibiotics.
Though Borrelia was not found when cultured, the RNA
transcripts for multiple genes were detected.15 In a recent
study, B. burgdorferi DNA was identified by xenodiagnosis
in a human PTLDS patient despite antibiotic treatment.17
Three morphological forms of persistent B. burgdorferi
were reported based on the observations from the experimental
studies. They are spirochete, spheroplast (or l-form), microcolony, and round-body forms.10,18,19 Though there are some
reports of spheroplast or round-body forms in humans, there
is no clear study demonstrating whether these forms exist and
cause clinical disease in humans.20 Recently, few systematic
studies showed the presence of drug-tolerant B. burgdorferi
persisters during in vitro culture. Sharma et al21 have demonstrated that killing of B. burgdorferi by antibiotics is biphasic,
with a small subpopulation of surviving persisters. This is one
of the systematic studies that has revealed the existence of Borrelia persisters in vitro. In addition to this study, researchers
showed the presence of antibiotic-tolerant persisters. Researchers have shown that the combination of three drugs, such as
daptomycin, doxycycline, and cefoperazone, eradicated the
most resistant microcolony form of B. burgdorferi persisters.7,22
The currently prescribed drugs amoxicillin, ceftriaxone, and
doxycycline are not able to eliminate the B. burgdorferi completely according to some studies,7,21–23 although other investigators have shown the complete eradication of B. burgdorferi
1308
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both in vitro and in vivo after relatively low dose or short course
treatment with antibiotics.24–26 The surviving antibiotic-tolerant
cells are not resistant mutants; upon regrowth, they form a new
persister subpopulation. So, based on these observations, it is
necessary to identify the potent drug candidates that can target
the Borrelia persisters.
Due to the unmet need, studies using high-throughput
screening (HTS) of drugs for B. burgdorferi are increasing,
especially screening of drugs against persisters.7,27–30 HTS
of medicinal compound libraries can help in identifying
candidate molecules that can potentially be effective against
the persisters and, therefore, can be used for therapeutic
purposes. Recent studies of a number of compounds have
facilitated the repurposing of drug molecules and their rapid
approval for the treatment of different diseased conditions.31,32
Moreover, the availability of structurally diverse entities in the
HTS compound libraries can help in identifying the potential
lead compounds that can be used for the antiborrelial drug
discovery process. The current study was, therefore, aimed
at testing multiple compound libraries for their potential to
inhibit the growth of stationary-phase B. burgdorferi. Four
drug-screening libraries were selected on the basis of the
available pre/clinical data, structural diversity, and mechanism of action of the compounds. Using recently developed
highly sensitive BacTiter-Glo assay, four chemical libraries,
such as the Library of Pharmacologically Active Compounds
(LOPAC1280), the National Institutes of Health Clinical Collection (NIHCC), the Microsource Spectrum, and the Biomol
Food and Drug Administration (FDA), were screened.33
We found 150 inhibitory compounds that were found to be
active against the stationary-phase form of Borrelia. The
minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) were determined for the
top 20 FDA-approved compounds. The identified compounds
can be further investigated for their therapeutic potential in
preclinical animal models and in patients with Lyme disease.
Moreover, the outcomes of the study can provide input for
both mechanistic and translational research that can help in
establishing clinically viable solutions to Lyme disease.

Materials and methods
Bacterial strains and culture
B. burgdorferi s.s. strains CA4 and CA8 originated biologically from Ixodes pacificus ticks, USA. The bacterial
strains were generously provided by Dr Robert Lane,
University of California, Berkeley, CA, USA. These strains
are infectious low passage numbers that were cultured in
Barbour-Stoenner-Kelly II (BSK-II) complete medium,
with 6% rabbit serum (Sigma-Aldrich, St Louis, MO, USA).
Drug Design, Development and Therapy 2016:10
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We have chosen these strains because these are infectious
and prevalent in California, USA. The cultures were grown in
sterile 50 mL Falcon tubes (Corning Incorporated, Corning,
NY, USA) and incubated at 33°C. All culture media were
sterilized with 0.2 µM filter units (EMD Millipore, Billerica,
MA, USA). The B. burgdorferi cultures were grown for
7–10 days to reach the stationary phase with cell density .108/mL for performing all the assays. For HTS drug
screening, 7–10-day-old stationary-phase B. burgdorferi
cultures were transferred to 384-well culture microplates.

Drugs and drug libraries
All the information regarding purchase, solubility, and stock
solutions of drugs used in this study have been provided in
Table 1. All the drug stocks were filter sterilized with 0.2 µM
filter units. The FDA-approved drug libraries, such as the
LOPAC1280, the NIHCC, the Microsource Spectrum, and the
Biomol FDA (now Enzo Life Sciences) were acquired from
High-Throughput Bioscience Center, Stanford University.
All the library stocks were maintained in dimethyl sulfoxide
solutions at 10 mM compound concentrations. Plate-to-plate
dilutions were performed in 384-well plates using an Evolution P3 system equipped with a 384-well head.

HTS of chemical libraries with
B. burgdorferi persisters

medium was added to white 384-well Corning plates (Corning
Incorporated) using the Matrix Wellmate, and ~100 nL of
each compound from the stock solution was added using
the pin tool in the Staccato System (CaliperLS, Caliper Life
Sciences Inc, Alameda, CA) to 1–22 columns. The last two
columns of the 384 wells were left for culturing the controls.
We screened one compound per well in a 384-well microplate
format. These are screened in a 7-point titration ranging from
25 µM, 12.5 µM, 7.25 µM, 3.625 µM, 1.81 µM, 0.9 µM, and
0.45 µM. To these plates, 25 µL of 106/mL B. burgdorferi
stationary-phase cultures were added using the Multidrop dispenser. Then the plates were incubated at 33°C for 96 hours in
a humidified CO2 incubator (Forma Scientific, Waltham, MA,
USA) having 5% CO2 and 95% air. After 96 hours, 25 µL of
BacTiter-Glo reagent (Promega Corporation, Fitchburg, WI,
USA) was added to the plates using the Multidrop dispenser.
The plates were shaken for 2 minutes and incubated at room
temperature for 5 minutes. Finally, the luminescence was
measured using a Flexstation 3 (Molecular Devices LLC,
Sunnyvale, CA, USA) (500 ms/well). The data were analyzed
using the Assay Explorer software. Hits were identified as
compounds that resulted in a decrease in the luciferase signal
compared to controls with no compound.

Determination of MIC and MBC

To identify the effect of chemical compounds on B. burgdorferi
stationary-phase cultures qualitatively, HTS was performed
using the following procedure. A total of 50 µL of BSK-II

The MIC of the small molecules identified through screening
was determined by culturing 106/mL Borrelia in BSK-II
medium with different concentrations (0.3–160 µM) of
drugs. For MIC, 1 mL of cultures with respective drugs are

Table 1 Details of drugs used
Serial number

Name

Supplier

Solubility

Stock solution (mM)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Tetraethylthiuram disulfide
Doxorubicin hydrochloride
Josamycin
Cefotaxime acid
Cefazolin sodium
Epirubicin hydrochloride
Erythromycin ethylsuccinate
A-23187 calcimycin
Gramicidin
Cefdinir
Gambogic acid
Cephalothin sodium
Ceftazidime
Ticarcillin disodium
Valinomycin
Moxifloxacin hydrochloride
Linezolide
Idarubicin HCl
Tosufloxacin tosylate
Azlocillin sodium

Cayman Chemical
Cayman Chemical
Sigma-Aldrich
Cayman Chemical
Cayman Chemical
Cayman Chemical
Santa Cruz Biotech
Cayman Chemical
Sigma-Aldrich
Sigma-Aldrich
Cayman Chemical
Santa Cruz Biotech
Cayman Chemical
Santa Cruz Biotech
Cayman Chemical
Santa Cruz Biotech
Santa Cruz Biotech
Sigma-Aldrich
Santa Cruz Biotech
Santa Cruz Biotech

DMSO
Water
Ethanol
DMSO
Water
Water
DMSO
DMSO
DMSO
DMSO
DMSO
Water
DMSO
Water
Ethanol
Water
Water
Water
DMSO
Water

10
10
20
20
10
10
20
10
20
20
20
10
5
20
20
20
15
20
10
10

Abbreviation: DMSO, dimethyl sulfoxide.
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grown in 48-well plates in triplicates, wrapped with paraffin
film and placed for 72 hours at 33°C in a humidified CO2
incubator (Forma Scientific) having 5% CO2 and 95% air.23
Cell proliferation was assessed using the bacterial counting
chamber (Petroff-Hausser Counter, Horsham, PA, USA) by
phase-contrast microscopy. At the same time, cell proliferation was also assessed using the BacTiter-Glo™ assay. The
counting was performed in all the 25 squares of the central
grid. The BacTiter-Glo™ assay is performed by mixing
100 µL of culture in each well with 100 µL of BacTiter-Glo™
reagent (Promega Corporation). Then, the assay is performed
according to the manufacturer’s instructions. Luminescence
was measured using a Flexstation 3 microplate reader at
luminescence 500 milliseconds.33
For determining MBC, 20 µL of the 106/mL Borrelia
cultures grown in BSK-II medium for 72 hours at different
drug concentrations were added to the fresh BSK-II medium
and subcultured for 3 weeks.23,34–36 After a 3 week incubation
period, the samples were observed microscopically for motile
spirochetes in the culture. The MIC and MBC determinations
were done thrice independently.

Time kill studies
Time kill studies were performed with borrelial isolate CA8
(B. burgdorferi s.s.) with azlocillin sodium and cefotaxime
acid. To determine the rate of antimicrobial activity, 106/mL
Borrelia cultures were grown in BSK-II medium with
drugs at different concentrations. BSK-II medium with no
drugs was used as a control. The antibacterial activity was
determined by counting bacteria at 24 hours, 48 hours, and
72 hours. The experiment was done once with triplicates.34

Result
Development of BacTiter-Glo™ assay
compatible to HTS
B. burgdorferi grows very slowly, typically taking from
12 hours to 18 hours to replicate. Due to this slow growth, it is
difficult to measure B. burgdorferi culture quantitatively using
direct optical density. To measure the bacterial viability and
antibiotic susceptibility of B. burgdorferi, several rapid colorimetric assays, such as fluorogenic dye SYTO 9 (LIVE/DEAD)
assay, Sytox Green/Hoechst 33342 assay, and SYBR Green I/
PI assay, have been developed.7,28,37 It was reported that SYBR
Green I/PI assay can only detect accurately the live/dead ratio
of 105 cells/mL.37 In parallel to these assays, we have developed a highly sensitive BacTiter-Glo™ assay, which has been
optimized for 384-well plate.33 It is a one-step, straightforward
method to assess bacterial viability by measuring ATP from
the given sample. As it is a single-step assay, BacTiter-Glo™
1310
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assay can screen drugs quickly and efficiently in a large scale.
We have recently reported that the BacTiter-Glo™ assay is a
very sensitive assay that can reliably detect signal in the range
of minimum ten Borrelia cells in phosphate-buffered saline
and 7×103 in BSK-II medium.33 The BacTiter-Glo™ assay
can only detect cells that can generate ATP. It has not been
tested whether BacTiter-Glo™ assay can detect nongrowing
Borrelia, which may produce low levels of ATP. Due to the
advantage of detecting low number of bacteria (7×103) by this
method, false-positive candidates are eliminated in the HTS.
The BacTiter-Glo assay was validated by calculating Z′ values
with the Assay Explorer software for CA4 and CA8 strains,
which were .0.6, considered to be a good value to perform
an HTS assay. The data indicate that the BacTiter-Glo™
assay provides a one-step, straightforward method to quantify
B. burgdorferi with good sensitivity and dynamic range.

High-throughput primary screening
of chemical libraries with B. burgdorferi
persisters to identify potent drugs
To identify safe and effective molecules for Lyme disease
treatment, repurposing FDA-approved drug molecules
might be a fast and viable alternative in developing novel
borrelicidal compounds. To achieve this, we utilized the
BacTiter-Glo™ assay system. All the screening of drugs
was done by stationary-phase CA8 borrelial cultures with
cell density .108/mL, which are grown in BSK-II medium
for 7–10 days. During screening, the last two rows in the
384-well plate were taken as control by not adding any
drugs. By using the HTS platform, we have screened 4,366
chemical compounds representing different libraries, including the Sigma LOPAC (1,280 compounds), the NIHCC (446
compounds), the Microsource Spectrum (2,000 compounds),
and the Biomol FDA (640 compounds). The screening was
repeated for seven times with a titration range from 0.45 µM
to 25 µM to confirm the reproducibility. That means each
drug is tested at different concentrations in seven different
plates. By successfully screening these libraries, we have
identified ~150 hit molecules that showed the inhibition
of bacterial growth .90% compared to the control. Out of
these 150 hit molecules, 101 (67.3%) small molecules are
FDA-approved compounds.
Based on the results from the primary screening, we chose
the top 20 candidates and reconfirmed these by secondary
screening with BacTiter-Glo™ assay. These candidates were
chosen based on the .95% inhibition of bacteria in primary
screening, FDA approval, and safety of the compounds
(Table 2). The doxycycline, which is one of the currently
Drug Design, Development and Therapy 2016:10
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Table 2 Structure and activity of Top 20 hits against B. burgdorferi
Serial
number
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1

Drugs

Structure

% inhibition

Control (no drug)
Doxycycline
Tetraethylthiuram
disulfide

–
–
S
N

S

S

MIC
(µM)

MBC
(µM)

0
94.14
99.80

0.625

1.25

99.70

0.625

1.25

99.63

15.0

20.0

99.47

2.0

3.0

99.20

1.25

12

99.10

0.3

0.625

99.04

15.0

20.0

N
S

2

Doxorubicin
hydrochloride

OH

O
O

O

OH

O

NH2
HCl

3

Josamycin
O

OH

OH
O

OH

O

N

HO

O

OH

O

O

O

O

O

O
O

O

O

O

HO

4

Cefotaxime acid

O
O

O

N

OH

O

O

N
N
H

O

S

H

N
S
H2N

5

Cefazolin sodium

O
O
N
N

6

O
N

N
H

N

ONa

N N

S

H

Epirubicin
hydrochloride

2+

2
2

2

1+

2

2+

S

S

N

+&O

2

7

2+
2

2+

Erythromycin

2+

2+

2

2
2

2
2

2+
2

2+

1

2+
2

+2
2

(Continued)
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Table 2 (Continued)
Serial
number

Drugs

8

A-23187
calcimycin

Structure

2
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2

2 2

1

Gramicidin

10

Cefdinir

MIC
(µM)

MBC
(µM)

98.82

10.0

20.0

98.67

1.25

2.5

98.50

3.0

25.0

98.41

10.0

20.0

98.38

2.5

.80

98.23

30.0

40.0

98.16

10.0

45.0

97.97

15.0

40.0

2

+1

9

2+
+
1

% inhibition

Formyl-L-X-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-Val-LTrp-D-Leu-L-Y-D-Leu-L-Trp-D-Leu-L-Trp-ethanolamine
X = Val/Ile, Y = Trp/Phe/Tyr
+1

6
1

+
1

6

2+

1
+2

11

2

1

2

2

Gambogic acid

2+
2
2

2

2

2

+
2+ 2

12

Cephalothin
sodium

2
2

13

1

2

6

21D

1
+

2
6

+

Ceftazidime

2

2
2+
1

Ticarcillin
disodium

2

2
1

1D2

6

15

+

2

2

2

2±

2
21D

6
+
1

2
2

2

2
2

2

2
+1

1+

2

2

2

1

1
+

Valinomycin

+1

6
1

2

6

+

+
1

1

+ 1

14

2

2

2

2
2

2

2
1
+

2

1+

2

(Continued)
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Table 2 (Continued)
Serial
number

Drugs

16

Moxifloxacin
hydrochloride

Structure
2

2

)
+

% inhibition

MIC
(µM)

MBC
(µM)

97.68

7.5

12.5

97.58

0.625

25.0

97.4

5.0

10.0

97.27

45.0

.80

95.25

1.25

2.5

2+

1

1

+&O

2
1+ +

17

Linezolid

2
2

+
1

)

1

1

2

2

18

Idarubicin
hydrochloride

2

2+

2
2+
+&O

2

2+

2

2
2+
1+

19

Tosufloxacin
tosylate

2

2

)

2+

1

+ 1

1

1

2

)

6

2+
2

)

20

Azlocillin sodium

1+
1
2

2
1+

+

+
1

6
1

2
2

21D
2

Abbreviations: MBC, minimum bactericidal concentration; MIC, minimum inhibitory concentration.

prescribed drugs inhibited 94.14% of borrelial growth
compared to the control (no drug), which is less than the
percentage of inhibition of the top 20 candidates (Table 2).
Percentage inhibition was also one of the criteria for selecting
top 20 candidates for testing. The results of the remaining
130 compounds are shown in Table S1. Of the Borrelia cultured with some of the drugs, the viability was evaluated with
BacTiter-Glo™ assay as shown in Figure 1. In Figure 1A,
tetraethylthiuram disulfide shows the complete borrelial cell
inhibition at 1.25 µM, while epirubicin hydrochloride and
doxorubicin hydrochloride are uniformly effective against
B. burgdorferi at 0.625 µM. Vehicle control (dimethyl sulfoxide) did not show any significant effect on the cell survival.

Drug Design, Development and Therapy 2016:10

Drugs azlocillin and cephalothin showed ~99% efficacy
at 0.31 µM (Figure 1B). After confirming from secondary
screening, the MIC and MBC values were determined by
microdilution method for all the potential candidates.

Determinations of MIC and MBC values
To confirm the efficacy of the screening, MIC and MBC
values were evaluated. The MIC is determined as the lowest
concentration at which no motile spirochete is observed
by microscopy. Of the top 20 candidates evaluated, the
MIC values of epirubicin hydrochloride and doxorubicin
hydrochloride are ,1 µM. For the drugs cefazolin sodium,
gramicidin, azlocillin sodium, cefotaxime, and cephalothin
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Figure 1 Inhibition assay of drugs on CA8 strain.
Notes: Effect of drugs on Borrelia cell viability was studied with drugs: (A) tetraethylthiuram disulfide, doxorubicin hydrochloride, and epirubicin hydrochloride and
(B) azlocillin sodium and cephalothin sodium. The control has no drugs. The results represent mean ± SD.
Abbreviation: SD, standard deviation.

sodium, tetraethylthiuram disulfide, and linezolid, the MIC
values are #3 µM. For the remaining drugs, the MIC values are $3 µM. The MBC was determined by subculturing
20 µL of the Borrelia cultures grown at different drug
concentrations in fresh BSK-II medium for 21 days.23,34 The
MBC was determined when no spirochete was observed
microscopically in the culture. Of the top 20 compounds, the
lowest MBC values (,1.5 µM) were observed for epirubicin
hydrochloride and doxorubicin hydrochloride. The drugs
gramicidin, azlocillin sodium, leucomycin, cefotaxime,
idarubicin, and tetraethylthiuram disulfide show the MBC
values of #10 µM. All the remaining drugs show the MBC
values of .10 µM. For the cephalothin sodium, the MIC

$

Time kill studies
To determine the rate of antimicrobial activity of azlocillin
sodium and cefotaxime acid, CA8 strain of Borrelia was
exposed to different concentrations (0.625 µM, 1.25 µM,
2.5 µM, and 5 µM) of each of the drugs. The initial Borrelia
inoculum did not even decrease 1-log10-unit at concentrations
0.625 µM and 1.25 µM for azlocillin sodium (Figure 2A).

%
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value is very low, but the MBC value is .80 µM, and for
tosufloxacin tosylate, both the MIC and MBC values are very
high. The compounds doxorubicin, cephalothin, ticarcillin,
and cefdinir were also reported in the HTS performed by
Feng et al.29,38
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Figure 2 Time kill curves for B. burgdorferi s.s. isolates CA8 with (A) azlocillin sodium and (B) cefotaxime acid.
Notes: The Borrelia was grown in the drug concentrations of 0.625 µM, 1.25 µM, 2.5 µM, and 5 µM. Experiment was performed with triplicates by the investigation of growth
using conventional cell counts, and data were reported as the mean of triplicate. The control has no drugs.
Abbreviation: B. burgdorferi, Borrelia burgdorferi.
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For cefotaxime acid at concentration 1.25 µM, the microbial
growth is decreased 1-log10-unit but not at 0.625 µM
(Figure 2B). Both azlocillin sodium and cefotaxime acid
reduced morphologically intact motile cells to 3-log10-unit
(99.9%) between 48 hours and 72 hours at concentrations
2.5 µM and 5 µM. These specified concentrations of 2.5 µM
and 5 µM are MIC values and twice the MIC values. In control, the Borrelia growth increased to 7-log10-unit.

Discussion
One of the major challenges in the discovery of potent therapeutically effective drug molecules is the lack of availability
of sensitive screening tools. Though the procedure becomes
fairly simple with the availability of HTS methods and large
collections of drug libraries, the development of drugs against
slow-growing organisms still remains an uphill task. Though
a number of drugs have been tested and approved against
various spirochetes, the currently available drug therapies,
such as amoxicillin and doxycyclin, was unable to kill B.
burgdorferi persisters in vitro.7,21 In addition to this, patients
with Lyme who are diagnosed later and treated may develop
arthritis. These patients treated later do not respond fully to a
first course of antibiotic therapy.21,39 Therefore, efforts need
to be made to develop an efficient platform for the screening
of small molecules that can prove to be very effective, yet
safe, in the treatment of Lyme disease.
In an effort to search for the lead molecules that can
potentially be used for clinical application, we developed
and used a faster, efficient, and reliable HTS platform for
the screening of drug molecules against Borrelia. Current
methods are not sensitive enough to detect the bacterial
counts of ,105/mL.37 Due to this limitation, many potentially
valuable hits would be lost during the compound-screening
process. To avoid this, we developed a robust BacTiter-Glo
assay. We exploited the dependence of B. burgdorferi on
ATP as the major determinant of cell viability and their metabolic activity by utilizing BacTiter-Glo assay.33 This assay
involves the addition of an active reagent that binds with ATP
molecules and releases a luminescent signal, indicating the
presence of the viable microbes in the medium. In order to
develop a faster, yet reliable assay, we optimized the assay
for a 384-well HTS format.33
After developing and optimizing the assay, we focused
on analyzing a diverse group of chemical compounds and
drug libraries in order to identify the most effective agents
that can inhibit the growth of Borrelia. For this purpose,
we screened four different compound libraries that had a
greater proportion (80%) of FDA-approved molecules in
them. Approximately 4,366 drug molecules belonging to
Drug Design, Development and Therapy 2016:10
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four different libraries, including the Sigma LOPAC, the
NIHCC, the Microsource Spectrum, and the Biomol FDA,
were screened. Of the four chemical libraries, except for
the Microsource Spectrum, all the other libraries are 100%
FDA approved. The compounds included in these libraries
varied in their chemical structures, pharmacological classes,
mechanisms of therapeutic action, and their origins. The
rationale for selecting such a diverse group was to ensure that
the identified compounds could find direct clinical applications or provide basis for lead compounds for drug design
and development process.
We then exploited the developed HTS platform to identify
the hit molecules that showed the inhibition of .90% based
on the bacterial cell viability. A total of 150 molecules, both
FDA approved and unapproved, were shortlisted from the
different libraries. However, the utilization of approved drug
molecules helps in shortening the timeline from bringing the
drug from the lab to the bedside. Moreover, the availability of
clinical pharmacological and toxicological data decreases the
overall cost of the drug discovery process. Therefore, out of
the obtained HTS hits, we selected 20 molecules based upon
their FDA approval status, MIC values (,20 µM), percentage
inhibition of stationary-phase cultures of Borrelia (.95%),
and their reported safety profiles. The list of compounds
that has been identified after an additional secondary screen
(BacTiter-Glo), microscopic evaluation, and MIC and MBC
determination is provided in Table 2. It was found that the
identified compounds have been reported to exploit a number of mechanisms to exhibit their pharmacological action
in other bacterial species. The identification of compounds
using multiple pathways for their borrelicidal effects provides
an opportunity for using these drugs in clinical setup as combination therapy or possible therapeutic equivalents.
Among the identified drug molecules, erythromycin and
kitasamycin appeared to be very active. The drug erythromycin was already used clinically for the treatment of Lyme
disease. In some laboratories, strains and clinical isolates of
B. burgdorferi show resistance to erythromycin.40 This drug
belongs to the macrolide group of antibiotics, which exhibit
their antibacterial potential by blocking the protein synthesis
assembly of the bacteria. By targeting peptidyltransferase of
the bacteria, macrolides tend to cause the termination of protein chain elongation and the detachment of the enzyme from
the ribosomes, resulting in the bacterial protein inhibition.41
Moreover, the drug molecules have also proved their effectiveness as immune modulators in the treatment of various
inflammatory conditions.42,43 The drugs, erythromycin and
kitasamycin, are readily absorbed, and they diffuse into
most of the body fluids.44–46 Additionally, their biochemical
submit your manuscript | www.dovepress.com
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features make them extremely capable for intracellular and
tissue penetration. The availability of the antibiotics in the
drug-sequestered sites can potentially be helpful in clearing
bacteria from skin and joints.47–49 Additionally, a high percentage inhibition of stationary-phase culture forms of the
bacteria and the low MIC and MBC values establish that
these drug molecules can be helpful in treating both dividing
and persistent forms of Borrelia.
One of the other drug molecules, linezolid, was found to
possess ~98% inhibition of the stationary-phase Borrelia in
the initial screen. Moreover, the drug was found to possess
the MIC and MBC values of 0.4 µg/mL and 8.4 µg/mL,
respectively. The probable mechanism of action of linezolid
is also by retarding the initiation step of protein translation. It
tends to bind to the active site of the 50S ribosomal assembly
and prevents the downstream translation process, resulting in
the termination of normal protein synthesis in the bacteria.44,47
Linezolid possesses commendable pharmacokinetic profile
with up to 100% bioavailability after oral administration and
has a high volume of distribution.48,49 It is efficiently distributed in most of the body tissues, including osteoarticular and
central nervous system.50,51 Another group of compounds
that demonstrated significant reduction in bacterial growth
included the anthracycline-based antitumor antibiotics,
ie, epirubicin, doxorubicin, and idarubicin. These drugs,
primarily used for treating cancer conditions, tend to nonselectively intercalate between the nucleotides and prevent
DNA replication. Moreover, they inhibit the topoisomerase II
(bacterial equivalent DNA gyrase) and prevent the relaxation
of DNA supercoiling, leading to decreased replication and
transcription processes.52 Additionally, these drugs cause
genome and transcriptome level damage by causing the
generation of free oxygen radicals and disassembly of histone proteins.53 All these anthracycline antibiotics possess
exceptional pharmacokinetic profile. Though these molecules
are very effective as cytotoxic agents for the treatment of
cancer conditions, their use is often limited by their ability
to cause cardiotoxicity, neutropenia, and other adverse drug
reactions.54 Modifications in the formulation or developing
safer therapeutic drug molecules based on the anthracycline
ring can be helpful in finding acceptable alternate strategies
against the drug-tolerant Borrelia persisters.7
Moxifloxacin, a fourth-generation fluoroquinolone, also
showed a good inhibitory effect on the stationary-phase cultures of Borrelia. The drug specifically targets DNA gyrase,
both topoisomerase II and topoisomerase IV, and causes the
cessation of uncoiling and the separation of double-stranded
DNA, resulting in the inhibition of bacterial replication
process.55 Moxifloxacin, also available in the oral formulation,
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has .80% bioavailability. The drug has been known to target
various bacteria in the tissues that are generally considered as
drug-sequestered sites, including brain, lungs, and bones.56 It
has also been proved to be up to ten times more potent and
effective in treating other intracellular bacteria involved in
latent infections, such as Mycobacterium tuberculosis, than
other drugs of the same group.57 Another fluoroquinolone,
tosufloxacin, also showed comparable inhibitory activity of
the borrelial stationary-phase cultures (.97% inhibition).
However, the MIC and MBC values of the compound were
greater than moxifloxacin. The drug also targets the DNA
gyrase and has appreciable pharmacokinetic properties.58
Based on these pharmacological properties, moxifloxacin
and tosufloxacin appear to be a safe and effective alternate
for the currently available amoxicillin- or doxycycline-based
antiborrelial therapeutic strategies.
The study also identified a number of drug molecules
that target the cell wall synthesis of bacterial species. Among
these, the parenteral antipseudomonal penicillins, azlocillin and ticarcillin, were found to be quite potent against
the stationary-phase and growing forms of B. burgdorferi.
These penicillins tend to target the transpeptidase enzyme
of the bacteria, resulting in the inability of the growing peptidoglycan layer of the cell wall to cross-link.59 Penicillins,
bearing a smaller molecular structure, tend to pass through
the cell wall and inhibit the enzyme. This leads to the
generation of spheroplast or cell wall-lacking forms of the
bacteria, which are highly susceptible to cytolysis and cell
death. Being β-lactam antibiotics, these drug molecules are
highly susceptible to the action of β-lactamase-like enzymes.
However, the use of aminoglycosides or clavulanates in the
antibiotic regimen has proved to be effective in overcoming
the issues of drug resistance.
Using our HTS method, we were also able to identify some
cephalosporins that were very active against the persistent
forms of Borrelia. Cephalothin, cefdinir, cefotaxime acid,
and ceftazidime had a bacterial inhibition value of .98%.
Cephalosporins follow a mechanism similar to penicillins
for demonstrating their antibacterial effects. However,
these drugs are more resistant to the action of β-lactamases.
Cephalothin, cefotaxime acid, and ceftazidime are the firstand third-generation parenteral cephalosporins. Cefdinir,
however, is a third-generation oral cephalosporin having up
to 25% bioavailability.60 A number of cephalosporins have
been proved to possess remarkable activity against a number
of bacteria, including B. burgdorferi.35
Another group of agents that were found to be active
against the stationary phase of B. burgdorferi, with .97%
inhibition, were the mobile ion carriers or ionophores.
Drug Design, Development and Therapy 2016:10
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Valinomycin and calcimycin act as ionophores that mediate
the transport of charged molecules across the bacterial cell
wall causing an imbalance in the electrochemical gradient.61
Gramicidin, following a similar mechanism of action, tends
to form a channel in the bacterial wall and help in the transfer of ions across the bacterial membrane. All three drug
molecules, valinomycin, calcimycin, and gramicidin, along
with osmotic imbalance cause an associated disruption in the
normal oxidative phosphorylation process of the bacterial cell
leading, ultimately, to the death of the bacteria. Though the
toxicity of ionophores is generally very well known in living
systems, these drug molecules can be investigated for their
potential to be used in combination therapy against various
serious infectious diseases.
An interesting drug candidate identified in the study was
the alcohol dehydrogenase inhibitor, disulfiram. Though
the drug is used as a treatment of alcohol abuse, recently
its anticancer potential has also been discovered. It has
been known to make complexes with metal ions and cause
the disruption of the proteasome, leading to death of the
cancer cells. Similarly, the metabolites of the drug molecule
have been known to significantly inhibit the growth of a
number of bacterial species, including the biofilm-forming
Pseudomonas aeruginosa.62 The drug molecule has a good
bioavailability, and it passes the blood–brain barrier to show
its effect in the central nervous system. Though most of the
studies are concerned to the use of the drug molecule in
alcoholism yet, being a safe, FDA-approved molecule, the
drug can be repurposed for its antibacterial potential.
As we observe that azlocillin sodium and cefotaxime acid
show low MIC values, we studied time kill studies to determine the rate of antimicrobial activity. In our observation,
both azlocillin sodium and cefotaxime acid reduced Borrelia
no 3-log10-unit (99.9%) between 48 hours and 72 hours at
concentrations 2.5 µM and 5 µM, respectively.
The identified compounds can potentially provide
effective antibacterial cover against the persister forms of
B. burgdorferi, if indeed such forms can be proven to exist in
patients treated for Lyme disease who remain symptomatic.
The drug molecules exploit multiple mechanisms to show
their inhibitory effects. Moreover, due to the broad variety
of molecules, multiple routes of administration and dosage
forms can be developed for effectively treating the Lyme
disease infections. In summary, this study has provided
a mean to screen a large number of compounds using a
highly sensitive, reliable, and rapid platform. The assay has
identified a number of FDA-approved drug molecules with
their potential to be repurposed for use against both Lyme
disease and the associated PTLDS. In addition to identify
Drug Design, Development and Therapy 2016:10

High-throughput screening of drugs for Lyme disease

drugs and evaluate the MIC and MBC values, further studies
should be done by using in vitro persisters’ model to prove
whether these drugs have potential to eliminate persisters or
not.21 However, additional preclinical and clinical data can
substantiate the use of these drug molecules for repurposing
and clinical acceptance, thereafter.
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Table S1 List of identified compounds showing .95% inhibition
Serial number

% of inhibition

Compound name

Library source

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

95.3
90.53
94.14
95.91
98.59
97.12
97.19
98.37
98.55
96.74
98.16
96.78
98.52
97
96.62
91.11
99.1
96.94
95.44
93.93
96.47
93.67
98.09
97.34
97.52
96.89
98.03
95.24
99.63
95.2
96.3
98.27
98.79
96.55
97.71
98.23
98.64
97.98
98.39
98.71
98.84
97.97
99.67
97.24
97.1
97.78
98.8
96.61
98.02
97.95
98.73
97.49
99.19
97.88
93.86

Ceftriaxone sodium
Diphenyleneiodonium chloride
Doxycycline hydrochloride
Idarubicin
Mitoxantrone
Minocycline hydrochloride
PD 404,182
Ammonium pyrrolidinedithiocarbamate
Vancomycin hydrochloride
WB 64
Erythromycin
Actinomycin D
Mitomycin C
Nafcillin sodium
Dirithromycin
Norfloxacin
Cefoxitin sodium
Amoxicillin
Clarithromycin
Ampicillin sodium
Novobiocin sodium
Oxacillin sodium
Oxytetracycline
Meclocycline sulfosalicylate
Gemifloxacin mesylate
Methacycline hydrochloride
Cephapirin sodium
Puromycin hydrochloride
Josamycin
Chloramphenicol palmitate
Chloramphenicol hemisuccinate
Chloramphenicol
Chlorhexidine
Benzoic acid, 2-hydroxy compound with 8-quinolinol (1:1)
Penicillin G potassium
Penicillin V potassium
Piperacillin sodium
Clindamycin hydrochloride
Cloxacillin sodium
Tyrothricin
Vancomycin hydrochloride
Phenylmercuric acetate
Phenethicillin potassium
Hetacillin potassium
Daunorubicin
Demeclocycline hydrochloride
Oleandomycin phosphate
Dicloxacillin sodium
Spectinomycin U
Aminacrine
Pyrithione zinc
Lincomycin hydrochloride
Tetracycline hydrochloride
Methicillin sodium
Thioguanine

LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
LOPAC
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
(Continued)
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Table S1 (Continued)
Serial number

% of inhibition

Compound name

Library source

56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113

92.47
98.37
96.1
98.11
98.18
97.68
98.45
98.14
97.89
98.59
98.37
96.78
98.21
98.16
97.76
97.81
97.8
92.47
98.37
98.86
88.63
98.23
98.56
98.3
95.3
97.85
98.19
76.96
99.2
98.61
93.81
97.69
98.69
99.05
97.6
97.09
99.5
98.24
96.28
93.86
92.74
97
96.68
99.55
98.29
96.85
98.51
96.51
98.17
98.43
96.01
98.37
98.25
96.63
98.96
98.96
99.72
99.34

Hycanthone mesylate
Erythromycin estolate
Gatifloxacin
Roxithromycin
Mitoxantrone
Moxifloxacin hydrochloride
Tilmicosin
Monensin sodium (monensin A is shown)
Spiramycin
Azithromycin
Ramipril
Bacampicillin hydrochloride
Ceftriaxone sodium trihydrate
Telithromycin
Oxaprozin
Thiamphenicol
Tylosin tartrate
Sarafloxacin hydrochloride
Cefditorin pivoxil
Montelukast sodium
Khayanthone
Ceftazidime
Pyrromycin 1-naphthacenecarboxylic acid
Khivorin
Kitasamycin
Florfenicol
Actinonin
Enrofloxacin
Cefazolin sodium
Alexidine hydrochloride
Pristimerin
Salinomycin, sodium
Dromilac ethidium bromide
Cephalosporin c sodium
Erythromycin stearate
Agelasine (stereochemistry of diterpene unknown)
Diphenyleneiodonium chloride
Actinomycin D
Puromycin
Hoechst 33342 (cell permeable) (bisbenzimide)
Gliotoxin
Mitomycin C
Monensin
Clindamycin hydrochloride
Lincomycin
Novobiocin sodium
Troleandomycin
Aclacinomycin
Spectinomycin
A-2371
Mitomycin C
Puromycin
Daunorubicin hydrochloride
Bortezomib
Auranofin
Meropenem
Mitoxantrone
Tylosin tartrate

Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
NIHCC
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Microsource
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
(Continued)
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Table S1 (Continued)
Serial number

% of inhibition

Compound name

Library source

114
115
116
117
118
119
120
121
122
123
124
125
126
127
128

96.94
98.15
97.22
98.73
99.47
98.48
98.64
96.99
97.5
96.94
97.77
97.6
95.68
98.79
97.14

Thiamphenicol glycinate
Oxacillin sodium
Penicillin V potassium
Piperacillin
Florfenicol
Ampicillin
Azithromycin
Gatifloxacin
Ceftazidime
Chloramphenicol
Roxithromycin
Sparfloxacin
Ciprofloxacin
Clarithromycin
Clinafloxacin

Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol
Biomol

Abbreviations: LOPAC, Library of Pharmacologically Active Compounds; NIHCC, NIH Clinical Collection.
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